GoAI
Get started
Amarin Corporation plc logo

Amarin Corporation plc

AMRN

NASDAQHealthcareDrug Manufacturers - General

Open in GoAI

Previous close

$14.09

+$0.03 · +0.21%

Aug 21, 4:00 PM ET

Pre-market

$13.01

−$1.08 · -7.67%

Aug 24, 4:30 AM ET

AMRN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

48

Fair Value

Momentum

40

Weakening

Sentiment

52

Mixed

Risk resilience

57

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
IE
CEO
Aaron D. Berg
Listed since
Apr 1, 1993
Employees
80

Market position

Day range

Current $14.09

52-week range

Current $14.09

Open
$14.04
Previous close
$14.06
Volume
36.56K
0.49× average
Average volume
74.28K
Average daily volume
Market cap
291.42M USD
Beta
0.77
Market reference 1
50-day average
$14.7412
-4.42% below average
200-day average
$14.8442
-5.08% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
166.96M USD
P/E (TTM)
-9.86×
P/B (TTM)
0.66×
P/S (TTM)
1.57×
EV / EBITDA
-5.06×
Earnings yield
-13.39%
Free cash flow yield
2.33%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
41.58%
Operating margin
-17.91%
Net margin
-14.57%
Return on equity
-8.45%
Return on assets
-5.78%
Return on invested capital
-2.93%

Financial health

Debt / equity
0.01×
Current ratio
3.34×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends91%43%-4%-52%Gross margin, FY2021: 79.20%Gross margin, FY2022: 65.68%Gross margin, FY2023: 53.94%Gross margin, FY2024: 35.60%Gross margin, FY2025: 56.57%Operating margin, FY2021: 1.80%Operating margin, FY2022: -28.68%Operating margin, FY2023: -18.45%Operating margin, FY2024: -40.15%Operating margin, FY2025: -6.53%Net margin, FY2021: 1.33%Net margin, FY2022: -28.66%Net margin, FY2023: -19.26%Net margin, FY2024: -35.95%Net margin, FY2025: -18.16%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 79.20%. Gross margin FY2022 65.68%. Gross margin FY2023 53.94%. Gross margin FY2024 35.60%. Gross margin FY2025 56.57%. Operating margin FY2021 1.80%. Operating margin FY2022 -28.68%. Operating margin FY2023 -18.45%. Operating margin FY2024 -40.15%. Operating margin FY2025 -6.53%. Net margin FY2021 1.33%. Net margin FY2022 -28.66%. Net margin FY2023 -19.26%. Net margin FY2024 -35.95%. Net margin FY2025 -18.16%.

Income trends

Revenue

213.65M USD-6.55%

Operating income

−13.94M USD+84.81%

Net income

−38.8M USD+52.79%
Income trends across reported periods652.09M USD376.47M USD100.85M USD−174.77M USDRevenue, FY2021: 583.19M USDRevenue, FY2022: 369.19M USDRevenue, FY2023: 306.91M USDRevenue, FY2024: 228.61M USDRevenue, FY2025: 213.65M USDOperating income, FY2021: 10.5M USDOperating income, FY2022: −105.87M USDOperating income, FY2023: −56.62M USDOperating income, FY2024: −91.8M USDOperating income, FY2025: −13.94M USDNet income, FY2021: 7.73M USDNet income, FY2022: −105.8M USDNet income, FY2023: −59.11M USDNet income, FY2024: −82.18M USDNet income, FY2025: −38.8M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 583.19M USD. Revenue FY2022 369.19M USD. Revenue FY2023 306.91M USD. Revenue FY2024 228.61M USD. Revenue FY2025 213.65M USD. Operating income FY2021 10.5M USD. Operating income FY2022 −105.87M USD. Operating income FY2023 −56.62M USD. Operating income FY2024 −91.8M USD. Operating income FY2025 −13.94M USD. Net income FY2021 7.73M USD. Net income FY2022 −105.8M USD. Net income FY2023 −59.11M USD. Net income FY2024 −82.18M USD. Net income FY2025 −38.8M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue213.65M USD228.61M USD306.91M USD369.19M USD583.19M USD
Cost of goods sold92.78M USD147.23M USD141.37M USD126.71M USD121.33M USD
Gross profit120.87M USD81.38M USD165.54M USD242.48M USD461.86M USD
Research and development19.81M USD20.87M USD22.22M USD30.41M USD29.31M USD
Selling, general, and administrative115M USD152.31M USD199.94M USD304.42M USD408.33M USD
Operating expenses134.81M USD173.18M USD222.16M USD348.35M USD451.36M USD
Interest income10.85M USD13.4M USD11.86M USD2.82M USD1.22M USD
Interest expense7K USD7K USD8K USD15K USD129K USD
Depreciation and amortization3.03M USD3.01M USD2.97M USD3.1M USD2.86M USD
Operating income−13.94M USD−91.8M USD−56.62M USD−105.87M USD10.5M USD
Net income−38.8M USD−82.18M USD−59.11M USD−105.8M USD7.73M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

18 ratings
Strong buy00%
Buy317%
Hold1372%
Sell211%
Strong sell00%

AMRN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding AMRN

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR Portfolio Developed World ex-US ETF logoState Street SPDR Portfolio Developed World ex-US ETFSPDW
Market value
236.01K
Weight
0.00%
AUM
41.92B USD
Expense ratio
0.03%
Price / 1D
$52.02+0.79%
State Street SPDR S&P International Small Cap ETF logoState Street SPDR S&P International Small Cap ETFGWX
Market value
112.3K
Weight
0.01%
AUM
927.26M USD
Expense ratio
0.40%
Price / 1D
$46.205+0.40%

Continue in GoAI

Research AMRN

research.disclaimer